Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals has filed an abbreviated new drug application with the FDA seeking approval to market its Drospirenone and Ethinyl Estradiol tablets combination oral contraceptive product prior to the expiration of patents owned by Bayer HealthCare Pharmaceuticals.
Subscribe to our email newsletter
Watson’s Drospirenone and Ethinyl Estradiol product is a generic version of Bayer’s Yasmin (drospirenone and ethinyl estradiol) tablet which is indicated for the prevention of pregnancy.